Form 4 for RGEN REPLIGEN CORP
Accepted 2026-04-22 13:26:04 ET · period of report 2026-04-21 · accession 0001193125-26-169682 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-22 13:26 | 2026-04-21 | RGEN | Loeillot Olivier | CEO, Dir | S - Sale | $140.00 | -3,832 | 54.2K | -7% | -$536.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-21 | S | D | 3,832 | $140.00 | 54,246 | D | — | — | (F1) Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025. |